45
Participants
Start Date
December 31, 2014
Primary Completion Date
September 21, 2020
Study Completion Date
September 22, 2020
Carfilzomib
Dexamethasone
If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
Prednisone
f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
Methylprednisolone
If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
Lenalidomide
given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
Pomalidomide
administered PO at 4mg daily on days 1-21 of a 28 day cycle
Hudson Valley Hem/Onc Associates, Poughkeepsie
Cancer Specialists of North Florida, Fleming Island
Gabrail Cancer Center, Canton
Blood & Cancer Center of East Texas, Tyler
James R Berenson, MD, Inc., West Hollywood
Wellness Oncology and Hematology, West Hills
California Cancer Associates for Research & Excellence (cCARE), Encinitas
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
Oncotherapeutics
INDUSTRY